Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PL9643

Other · developed by Palatin Technologies

Phase 3 Most advanced trial (none active)
PTN Developer
1 Registered trials

What is PL9643?

PL9643 is an investigational drug studied in Dry Eye, Dry Eye Syndromes.

At a glance

Also known as
Active study medication
Drug type
Other
Therapy area
Ophthalmology
Developer
Palatin Technologies, Inc (PTN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05201170 Phase 3 Dry Eye Completed PTN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry EyeDry Eye Syndromes

More from Palatin Technologies

PL-3994 Phase 2 PL8177 Phase 2

Follow PTN, the company behind PL9643

See PTN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.